PE重组免疫毒素在肿瘤导向治疗中的应用  

Roles of PE-based recombinant immunotoxins in the targeting therapy of tumor

作　　者：张小平[1] 杜冰[1] 钱旻[1] 

机构地区：[1]华东师范大学生命科学学院免疫学实验室,上海200062

出　　处：《免疫学杂志》2004年第z1期52-55,共4页Immunological Journal

基　　金：上海市科学技术发展基金项目重点课题(00JC14049);上海-SK研究与发展基金项目(2002003-5);上海市教育发展基金会曙光计划项目(02SG21)资助

摘　　要：绿脓杆菌外毒素A(PE)经过修饰后失去了与细胞结合的能力,将单克隆抗体的Fv段或细胞因子作为导向分子与修饰后的PE通过DNA重组技术融合,获得重组的免疫毒素,这种免疫毒素通过导向分子将毒素带到靶细胞,并杀伤靶细胞,因而被广泛运用于肿瘤的导向治疗。Pseudomonas exotoxin A loses the ability to bind to cells after modification. The PE was fused with homing molecules such as Fv of monoclonal antibody or cytokine through the DNA recombinant technology, which produces the recombinant immunotoxin. The recombinant immunotoxin kills the targeted cells after the homing molecules carry PE to them. So the recombinant immunotoxin is widely being used in the targeting therapy of tumor.

关 键 词：PE衍生物 导向分子 重组免疫毒素 导向治疗 

分 类 号：R730.5[医药卫生—肿瘤]